- Home
- PROP vs GOSS Comparison
PROP vs GOSS Comparison
Compare PROP & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PROP | GOSS |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.6M | 101.2M |
| IPO Year | 2008 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PROP | GOSS |
|---|---|---|
| Price | $1.30 | $0.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $6.75 | $4.19 |
| AVG Volume (30 Days) | 7.2M | ★ 10.6M |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 49.06 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $7,939,000.00 | ★ $48,471,000.00 |
| Revenue This Year | $81.83 | N/A |
| Revenue Next Year | $18.00 | $144.43 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 413.59 | N/A |
| 52 Week Low | $1.22 | $0.32 |
| 52 Week High | $4.68 | $3.87 |
Technical Indicators
Market Signals| Indicator | PROP | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 38.54 | 41.59 |
| Support Level | N/A | $0.33 |
| Resistance Level | $2.11 | $0.60 |
| Average True Range (ATR) | 0.29 | 0.04 |
| MACD | -0.10 | 0.06 |
| Stochastic Oscillator | 5.20 | 88.02 |
Price Performance
Historical ComparisonAbout PROP Prairie Operating Co.
Prairie Operating Co is a Houston-based independent energy company engaged in the development and acquisition of oil and natural gas resources in the United States. The Company's assets and operations are concentrated in the oil and liquids-rich regions of the Denver-Julesburg (DJ) Basin, with a focus on the Niobrara and Codell formations. The Company is committed to the responsible development of its oil and natural gas resources and is focused on maximizing returns through consistent growth, capital discipline, and sustainable cash flow generation.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.